Showing results (2771-2780 of 5,702) with videos related to

Sort By:
Pageof 571
The Oncologist|August 17, 2026
An Assessment of Time Toxicity in Patients Receiving [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)Zachary Scharf, Miguel Muniz, Elizabeth Tchitchkan, et al.
The Oncologist|August 18, 2026
Use, survival, and adverse events of dostarlimab monotherapy in advanced or recurrent endometrial cancer: a nationwide cohort study in FranceAllison Singier, Stéphane Vignot, David Desplas, et al.
The Oncologist|August 18, 2026
FOLFOXIRI Plus Panitumumab for Left-sided RAS-wild-type Metastatic Colorectal CancerHoward S Hochster, Patrick J Blatchford, Stacey Stein, et al.
The Oncologist|August 21, 2026
Clinical management of adverse events in patients with advanced HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabineAlicia F C Okines, Erin Roesch, Karen Watkins, et al.
The Oncologist|August 27, 2026
Paired genomic profiling of primary tumor and lymph-node metastases identifies candidate prognostic features in penile squamous cell carcinomaKexin Lou, Linghui Liang, Hongzhou Cai, et al.
The Oncologist|September 2, 2026
Functional Brain Network Alterations Linked to Cancer-Related Cognitive Impairment in Breast Cancer PatientsAlberto Benelli, Julianne Reilly, Jorge Ortega-Márquez, et al.
The Oncologist|July 23, 2026
DDR pathway alterations in urothelial carcinoma: A road to precision oncology or a dead-end street?Patricia Guerrero Serrano, Pilar Sotoca, Adriana García, et al.
The Oncologist|July 21, 2026
Clinical outcomes of sacituzumab govitecan in older patients with metastatic triple-negative breast cancer: a multinational real-world studyAleksandra Konieczna, Małgorzata Pieniążek, Justyna Żubrowska, et al.
The Oncologist|August 27, 2026
Osimertinib plus anlotinib in untreated, EGFR-mutated, advanced non-small-cell lung cancer with concurrent alterations: a multicenter phase II studyXiaojun Yang, Qinquan Tan, Shiyuan Chen, et al.
The Oncologist|August 31, 2026
Feasibility of EHR-Based Prescreening for an Adjuvant Breast Cancer Trial in a Safety-Net Health SystemHussain Alkhafaji, Lindsay C K Reynolds, Melissa Howell, et al.
Pageof 571